Amgen pays Nektar $50M for polymer

The cancer drug developer Nektar Therapeutics ($NKTR) has inked a deal to supply a proprietary polymer to Amgen ($AMGN) for $50 million. And in the event it fails to deliver the polymer as contracted, Amgen gains the right of access to the manufacturing facility. Nektar also stands to earn more from the deal if Amgen ups its order. Report